Cargando…

Canakinumab for refractory RA: a case report

Rheumatoid arthritis is a common autoimmune disease leading often to joint destruction and reduced quality of life. We report a case of a young woman with rheumatoid arthritis with fever and rapid, destructive joint involvement verified with magnetic resonance imaging. She had failed therapy with me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marketos, Nikolaos, Bournazos, Ilias, Ioakimidis, Dimitrios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Mediterranean Journal of Rheumatology (MJR) 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046045/ https://www.ncbi.nlm.nih.gov/pubmed/32185319 http://dx.doi.org/10.31138/mjr.29.3.170

Ejemplares similares

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases
por: Papa, Riccardo, et al.
Publicado: (2020)

Case report on the use of canakinumab for treatment of recurrent fevers and proteinuria in refractory systemic lupus erythematosus
por: Yavari, Kimia, et al.
Publicado: (2023)

Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment
por: Alpa, Mirella, et al.
Publicado: (2015)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Canakinumab: Pulmonary bacterial superinfection secondary to compassionate use: case report
Publicado: (2021)

Canakinumab for the treatment of different refractory autoinflammatory disorders
por: Grein, Ingrid HR, et al.
Publicado: (2014)

A case report of locally invasive Aspergillus fumigatus infection in a patient on canakinumab
por: Chandrakumaran, Anchalia, et al.
Publicado: (2018)

A Case of Hyperimmunoglobulinemia D Syndrome Successfully Treated with Canakinumab
por: Tsitsami, Elena, et al.
Publicado: (2013)

Improvement of Liver Involvement in Familial Mediterranean Fever After the Introduction of Canakinumab: A Case Report
por: Massaro, Maria Grazia, et al.
Publicado: (2020)

A Case of Peritoneal Tuberculosis Developed after Infliximab Therapy for Refractory RA
por: Min, Ji-Yeon, et al.
Publicado: (2012)

A case of Schnitzler’s syndrome without monoclonal gammopathy successfully treated with canakinumab
por: Fujita, Yuya, et al.
Publicado: (2021)

The Role of Novel Autoantibodies in the Diagnostic Approach and Prognosis of Patients with Raynaud’s Phenomenon
por: Koulouri, Vasiliki, et al.
Publicado: (2020)

Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
por: Niccoli, Laura, et al.
Publicado: (2015)

Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience
por: Kavrul Kayaalp, Gülşah, et al.
Publicado: (2023)

Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report
por: Ulusoy, Ezgi, et al.
Publicado: (2015)

Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome
por: Gorodetskiy, Vadim R., et al.
Publicado: (2018)

Early Treatment of Systemic Juvenile Idiopathic Arthritis with Canakinumab and Complete Remission After 2 Years of Treatment Suspension: Case Report of an Adolescent Girl
por: Maggio, Maria Cristina, et al.
Publicado: (2019)

Therapeutic approach to Gradenigo's syndrome: a case report
por: Kantas, Ilias, et al.
Publicado: (2010)

Indications and efficacy of canakinumab in Familial Mediterranean Fever: report of three cases
por: Tsinti, Maria, et al.
Publicado: (2014)

The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever
por: Sozeri, Betul, et al.
Publicado: (2016)

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report
por: Hansmann, Sandra, et al.
Publicado: (2011)

Live‐attenuated vaccines in a cryopyrin‐associated periodic syndrome patient receiving canakinumab treatment during infancy
por: Watanabe, Misa, et al.
Publicado: (2017)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Canakinumab in a subgroup of patients with COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Canakinumab: can it untie the Gordian knot of cardiovascular disease in patients with familial Mediterranean fever?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Rituximab and Canakinumab Use During Lactation: No Detectable Serum Levels in Breastfed Infants
por: Bosshard, Nicole, et al.
Publicado: (2021)

Canakinumab and cardiovascular outcomes: results of the CANTOS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Canakinumab and mycophenolate mofetil in managing proteinuria/renal amyloidosis secondary to adult-onset Still’s disease
por: Feng, Jin, et al.
Publicado: (2023)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome
por: Caracciolo, Massimo, et al.
Publicado: (2020)

Craniospinal irradiation in the treatment of chemotherapy refractory leptomeningeal metastasis from breast cancer: A case report
por: Tesolin, Daniel, et al.
Publicado: (2021)

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
por: Yücel, Burcu Bozkaya, et al.
Publicado: (2021)

Acute COVID-Related Hip Arthritis. Case Report and Literature Review
por: Kalavrytinos, Dimitrios, et al.
Publicado: (2023)

Clinical experiences with canakinumab as a treatment for autoinflammatory disorders
por: Saperia, C, et al.
Publicado: (2015)

Canakinumab in addition to phosphate-binding and phosphaturia-inducing therapy were effective in achieving remission in a child with a large familial calcinotic tumour
por: Ochoa, Maria, et al.
Publicado: (2023)

P02-008 - Dramatic response to canakinumab in MKD
por: Makay, B, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_reanaaamff36700g967eum83h8